Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medicare Will Test Payment Model For Accelerated Approvals To ‘Expedite’ Confirmatory Trials

Executive Summary

The Center for Medicare and Medicaid Innovation also will develop demonstrations focused on payment arrangements for cell and gene therapy in Medicaid and promoting generic drugs in Medicare Part D.

You may also be interested in...

Private Payers Have ‘Significant’ Role In Ensuring Confirmatory Trials Get Done, FDA’s Califf Says

In an unusual appearance at AHIP annual conference on Medicare and Medicaid, the US FDA commissioner discusses accelerated approvals and argues that payers should be more than ‘passive recipients’ of research. Insurers should help develop the confirmatory data for drugs, Califf says.

FDA, CMS And Accelerated Approval: Flipping The Script

The US Medicare agency’s restrictive coverage policy for Alzheimer’s antibodies is a clear threat to the FDA accelerated approval pathway. Now the payor is going to try a different approach to strengthen the pathway.

President Biden’s Proposal To Expand Medicare Price Controls A Sign Of Things To Come

Even though it is unlikely that the policies will succeed in the currently divided Congress, the proposal reinforces industry’s concerns that once a foundation for Medicare price negotiation is established, policymakers will try to build on it.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts